Balancing novelty with confined chemical space in modern drug discovery
暂无分享,去创建一个
Karina Martinez-Mayorga | Nathalie Meurice | José L Medina-Franco | J. Medina-Franco | K. Martínez-Mayorga | N. Meurice | J. Medina‐Franco
[1] Bryan L. Roth,et al. Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.
[2] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[3] Matteo Floris,et al. Swimming into peptidomimetic chemical space using pepMMsMIMIC , 2011, Nucleic Acids Res..
[4] José L. Medina-Franco,et al. Chemoinformatic Analysis of GRAS (Generally Recognized as Safe) Flavor Chemicals and Natural Products , 2012, PloS one.
[5] Simona Bohanec,et al. Structure generation of constitutional isomers from structural fragments , 1991, J. Chem. Inf. Comput. Sci..
[6] Dik-Lung Ma,et al. Drug repositioning by structure-based virtual screening. , 2013, Chemical Society reviews.
[7] José L Medina-Franco,et al. Design and synthesis of α‐conotoxin GID analogues as selective α4β2 nicotinic acetylcholine receptor antagonists , 2014, Biopolymers.
[8] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[9] Michele Saviano,et al. Conformationally Constrained CCK8 Analogues Obtained from a Rationally Designed Peptide Library as Ligands for Cholecystokinin Type B Receptor , 2006, ChemMedChem.
[10] Peter Ertl,et al. The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.
[11] Francesco Marchetti,et al. Towards the Systematic Exploration of Chemical Space , 2012 .
[12] Philippe Roche,et al. 2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions , 2012, Nucleic Acids Res..
[13] Michael Entzeroth,et al. Focused Libraries: The Evolution in Strategy from Large-Diversity Libraries to the Focused Library Approach , 2006 .
[14] Alicia P. Higueruelo,et al. Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database , 2009, Chemical biology & drug design.
[15] Thorsten Nowak,et al. Expanding medicinal chemistry space. , 2013, Drug discovery today.
[16] Andreas Bender,et al. Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..
[17] P. Wipf,et al. Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. , 2013, Journal of the American Chemical Society.
[18] D. H. Williams,et al. Iminosugars past, present and future: medicines for tomorrow. , 2011, Drug discovery today.
[19] A. Ganesan. The impact of natural products upon modern drug discovery. , 2008, Current opinion in chemical biology.
[20] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[21] J. Medina-Franco,et al. Systematic mining of generally recognized as safe (GRAS) flavor chemicals for bioactive compounds. , 2013, Journal of agricultural and food chemistry.
[22] M. Carmen Galan,et al. Carbohydrate Chemistry in Drug Discovery , 2011 .
[23] Deepak Bandyopadhyay,et al. Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes , 2012, Journal of biomolecular screening.
[24] Rachelle J Bienstock,et al. Computational drug design targeting protein-protein interactions. , 2012, Current pharmaceutical design.
[25] L. Cipolla,et al. Carbohydrate-based bioactive compounds for medicinal chemistry applications. , 2011, Mini reviews in medicinal chemistry.
[26] Ian H Gilbert,et al. Finding new hits in neglected disease projects: target or phenotypic based screening? , 2011, Current topics in medicinal chemistry.
[27] Stephen P. Hale,et al. The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.
[28] Jean-Louis Reymond,et al. Visualization and Virtual Screening of the Chemical Universe Database GDB-17 , 2013, J. Chem. Inf. Model..
[29] Alberto Del Rio,et al. Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives , 2012, Current pharmaceutical design.
[30] Michal Sabat,et al. Diversity Space and Its Application to Library Selection and Design , 2006, J. Chem. Inf. Model..
[31] Bruno Giethlen,et al. Chapter 15 – Molecular Variations Based on Isosteric Replacements , 2008 .
[32] J. Medina-Franco,et al. Inhibitors of DNA methyltransferases: insights from computational studies. , 2012, Current medicinal chemistry.
[33] J. Medina-Franco,et al. The prince and the pauper. A tale of anticancer targeted agents , 2008, Molecular Cancer.
[34] Jürgen Bajorath,et al. A Perspective on Computational Chemogenomics , 2013, Molecular informatics.
[35] Jeffrey Aubé,et al. Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.
[36] Craig W Lindsley,et al. Application of combinatorial chemistry science on modern drug discovery. , 2008, Journal of combinatorial chemistry.
[37] Ingo Muegge. Synergies of virtual screening approaches. , 2008, Mini reviews in medicinal chemistry.
[38] Julian Tirado-Rives,et al. Virtual screening and optimization yield low-nanomolar inhibitors of the tautomerase activity of Plasmodium falciparum macrophage migration inhibitory factor. , 2012, Journal of medicinal chemistry.
[39] Stuart L. Schreiber,et al. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.
[40] Alberto Del Rio,et al. Freely accessible databases of commercial compounds for high- throughput virtual screenings. , 2012, Current topics in medicinal chemistry.
[41] José L. Medina-Franco,et al. A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions , 2013, Journal of Cell Science.
[42] A Lavecchia,et al. Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.
[43] D. E. Clark. What has virtual screening ever done for drug discovery? , 2008, Expert opinion on drug discovery.
[44] Schmid,et al. "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.
[45] José L Medina-Franco,et al. Molecular Scaffold Analysis of Natural Products Databases in the Public Domain , 2012, Chemical biology & drug design.
[46] Stephen R. Johnson,et al. Chapter 9:Compound Library Design – Principles and Applications , 2008 .
[47] José L. Medina-Franco,et al. ADVANCES IN COMPUTATIONAL APPROACHES FOR DRUG DISCOVERY BASED ON NATURAL PRODUCTS , 2013 .
[48] G. Verdine,et al. Stapled peptides for intracellular drug targets. , 2012, Methods in enzymology.
[49] Richard A. Houghten,et al. Combinatorial Chemistry: Libraries from Libraries, the Art of the Diversity‐Oriented Transformation of Resin‐Bound Peptides and Chiral Polyamides to Low Molecular Weight Acyclic and Heterocyclic Compounds , 2004 .
[50] José L. Medina-Franco,et al. Data Mining of Protein-Binding Profiling Data Identifies Structural Modifications that Distinguish Selective and Promiscuous Compounds , 2012, J. Chem. Inf. Model..
[51] Sivaraman Dandapani,et al. Grand challenge commentary: Accessing new chemical space for 'undruggable' targets. , 2010, Nature chemical biology.
[52] Valery M. Dembitsky,et al. Anticancer activity of natural and synthetic acetylenic lipids , 2006, Lipids.
[53] Yoo Jakyung,et al. Chemoinformatic Approaches for Inhibitors of DNA Methyltransferases: Comprehensive Characterization of Screening Libraries , 2011 .
[54] David B Jackson,et al. Drug profiling: knowing where it hits. , 2010, Drug discovery today.
[55] Nathan Brown,et al. On scaffolds and hopping in medicinal chemistry. , 2006, Mini reviews in medicinal chemistry.
[56] Paul A Clemons,et al. Complex phenotypic assays in high-throughput screening. , 2004, Current opinion in chemical biology.
[57] Stephen D. Roughley,et al. The Medicinal Chemist′s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates , 2011 .
[58] Gilles Gasser,et al. The potential of organometallic complexes in medicinal chemistry. , 2012, Current opinion in chemical biology.
[59] Clemencia Pinilla,et al. Integrating computational and mixture-based screening of combinatorial libraries , 2011, Journal of molecular modeling.
[60] Philippe Vayer,et al. Toward in silico structure-based ADMET prediction in drug discovery. , 2012, Drug discovery today.
[61] Jaime Pérez-Villanueva,et al. Chemoinformatic characterization of activity and selectivity switches of antiprotozoal compounds. , 2014, Future medicinal chemistry.
[62] David J Craik,et al. Therapeutic potential of conopeptides. , 2012, Future medicinal chemistry.
[63] Sarah R. Langdon,et al. Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..
[64] Calvin Yu-Chian Chen,et al. TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.
[65] F Ivy Carroll,et al. From rapid In Vitro screening to rapid In Vivo screening in the drug discovery process , 2009, Neuropsychopharmacology.
[66] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[67] Michael D Shultz,et al. Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters. , 2013, Bioorganic & medicinal chemistry letters.
[68] Jürgen Bajorath,et al. Mapping of pharmacological space , 2011, Expert opinion on drug discovery.
[69] Giovanna Zinzalla,et al. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. , 2009, Future medicinal chemistry.
[70] W. Pitt,et al. Heteroaromatic rings of the future. , 2009, Journal of medicinal chemistry.
[71] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[72] D Rognan,et al. Towards the Next Generation of Computational Chemogenomics Tools , 2013, Molecular informatics.
[73] Andrea Trabocchi,et al. Diversity-Oriented Synthesis: Basics and Applications in Organic Synthesis, Drug Discovery, and Chemical Biology , 2013 .
[74] Bruno Giethlen,et al. Molecular Variations Based on Isosteric Replacements , 2008 .
[75] Karina Martinez-Mayorga,et al. Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure. , 2013, European journal of medicinal chemistry.
[76] José L. Medina-Franco,et al. Chemoinformatic Characterization of the Chemical Space and Molecular Diversity of Compound Libraries , 2013 .
[77] Hong-Yu Zhang,et al. Exploring the Biologically Relevant Chemical Space for Drug Discovery , 2013, J. Chem. Inf. Model..
[78] J. Reichert,et al. Future directions for peptide therapeutics development. , 2013, Drug discovery today.
[79] M. Hann,et al. Finding the sweet spot: the role of nature and nurture in medicinal chemistry , 2012, Nature Reviews Drug Discovery.
[80] Paul Ernsberger,et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[81] Clemencia Pinilla,et al. Rapid Scanning Structure-Activity Relationships in Combinatorial Data Sets: Identification of Activity Switches , 2013, J. Chem. Inf. Model..
[82] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[83] Peter Ertl,et al. Evolution of the physicochemical properties of marketed drugs: can history foretell the future? , 2011, Drug discovery today.
[84] J. Medina-Franco,et al. Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.
[85] Iskander Yusof,et al. Considering the impact drug-like properties have on the chance of success. , 2013, Drug discovery today.
[86] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[87] Austin B. Yongye,et al. Modeling of peptides containing D-amino acids: implications on cyclization , 2009, J. Comput. Aided Mol. Des..
[88] Markus Hartenfeller,et al. DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..
[89] Eric Meggers,et al. Exploring biologically relevant chemical space with metal complexes. , 2007, Current opinion in chemical biology.
[90] Pasi Soininen,et al. Activity and stability of human kallikrein‐2‐specific linear and cyclic peptide inhibitors , 2007, Journal of peptide science : an official publication of the European Peptide Society.
[91] C. Heinis,et al. Polycyclic Peptide Therapeutics , 2013 .
[92] José L. Medina-Franco,et al. Increased Diversity of Libraries from Libraries: Chemoinformatic Analysis of Bis‐Diazacyclic Libraries , 2011, Chemical biology & drug design.
[93] Stefan Wetzel,et al. Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.
[94] Matthew D Segall,et al. Multi-parameter optimization: identifying high quality compounds with a balance of properties. , 2012, Current pharmaceutical design.
[95] Rajarshi Guha,et al. Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository , 2009, J. Chem. Inf. Model..
[96] Clemencia Pinilla,et al. Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. , 2008, Journal of combinatorial chemistry.
[97] José L. Medina-Franco,et al. Visualization of the Chemical Space in Drug Discovery , 2008 .
[98] Scott Boyer,et al. A critical assessment of modeling safety-related drug attrition , 2013 .
[99] José L Medina-Franco,et al. Progress in the Visualization and Mining of Chemical and Target Spaces , 2013, Molecular informatics.
[100] José L. Medina-Franco,et al. Scaffold Diversity Analysis of Compound Data Sets Using an Entropy-Based Measure , 2009 .
[101] M Berrie. Division of chemical information. , 2000, IDrugs : the investigational drugs journal.
[102] A. H. Lipkus,et al. Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .
[103] Fabian López-Vallejo,et al. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. , 2011, Combinatorial chemistry & high throughput screening.
[104] Bryan L. Roth,et al. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[105] Ian Collins,et al. Macrocycles in new drug discovery. , 2012, Future medicinal chemistry.
[106] K. M. Smith,et al. Novel software tools for chemical diversity , 1998 .
[107] Sébastien Granier,et al. A new era of GPCR structural and chemical biology. , 2012, Nature chemical biology.
[108] Fabrizio Giordanetto,et al. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.
[109] Landon R. Whitby,et al. Comprehensive peptidomimetic libraries targeting protein-protein interactions. , 2012, Accounts of chemical research.
[110] Olivier Sperandio,et al. Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.
[111] C. Franceschi,et al. Immunoproteasome in cancer and neuropathologies: a new therapeutic target? , 2012, Current pharmaceutical design.
[112] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[113] Harshil Dhruv,et al. Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis* , 2013, The Journal of Biological Chemistry.
[114] Hiroshi Murakami,et al. Ribosomal synthesis of bicyclic peptides via two orthogonal inter-side-chain reactions. , 2008, Journal of the American Chemical Society.
[115] J. Bajorath,et al. Scaffold hopping using two-dimensional fingerprints: true potential, black magic, or a hopeless endeavor? Guidelines for virtual screening. , 2010, Journal of medicinal chemistry.
[116] José L Medina-Franco,et al. Systematic characterization of structure-activity relationships and ADMET compliance: a case study. , 2013, Drug discovery today.
[117] J. Medina-Franco,et al. Expanding the medicinally relevant chemical space with compound libraries. , 2012, Drug discovery today.
[118] Alfredo Ortega,et al. Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum(Labiatae) , 1982 .
[119] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.